FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078331588> ?p ?o ?g. }

• W2078331588 endingPage "e52680" @default.
• W2078331588 startingPage "e52680" @default.
• W2078331588 abstract "The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson’s disease. This study aimed at evaluating the effect of IRC-082451 (base of BN82451), a novel multitargeting hybrid molecule, on L-DOPA-induced dyskinesias (LIDs) and hypolocomotor activity in a non-human primate model of PD. IRC-082451 displays multiple properties: it inhibits neuronal excitotoxicity (sodium channel blocker), oxidative stress (antioxidant) and neuroinflammation (cyclooxygenase inhibitor) and is endowed with mitochondrial protective properties. Animals received daily MPTP injections until stably parkinsonian. A daily treatment with increasing doses of L-DOPA was administered to parkinsonian primates until the appearance of dyskinesias. Then, different treatment regimens and doses of IRC-082451 were tested and compared to the benchmark molecule amantadine. Primates were regularly filmed and videos were analyzed with specialized software. A novel approach combining the analysis of dyskinesias and locomotor activity was used to determine efficacy. This analysis yielded the quantification of the total distance travelled and the incidence of dyskinesias in 7 different body parts. A dose-dependent efficacy of IRC-082451 against dyskinesias was observed. The 5 mg/kg dose was best at attenuating the severity of fully established LIDs. Its effect was significantly different from that of amantadine since it increased spontaneous locomotor activity while reducing LIDs. This dose was effective both acutely and in a 5-day sub-chronic treatment. Moreover, positron emission tomography scans using radiolabelled dopamine demonstrated that there was no direct interference between treatment with IRC-082451 and dopamine metabolism in the brain. Finally, post-mortem analysis indicated that this reduction in dyskinesias was associated with changes in cFOS, FosB and ARC mRNA expression levels in the putamen. The data demonstrates the antidyskinetic efficacy of IRC-082451 in a primate model of PD with motor complications and opens the way to the clinical application of this treatment for the management of LIDs." @default.
• W2078331588 created "2016-06-24" @default.
• W2078331588 creator A5001522381 @default.
• W2078331588 creator A5018955311 @default.
• W2078331588 creator A5019291640 @default.
• W2078331588 creator A5019554843 @default.
• W2078331588 creator A5024687365 @default.
• W2078331588 creator A5028010133 @default.
• W2078331588 creator A5051329293 @default.
• W2078331588 creator A5051377002 @default.
• W2078331588 creator A5061400306 @default.
• W2078331588 creator A5065418218 @default.
• W2078331588 creator A5066770385 @default.
• W2078331588 creator A5067988831 @default.
• W2078331588 creator A5076819006 @default.
• W2078331588 creator A5078737983 @default.
• W2078331588 creator A5084660598 @default.
• W2078331588 date "2013-01-03" @default.
• W2078331588 modified "2023-10-15" @default.
• W2078331588 title "IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates" @default.
• W2078331588 cites W1587395327 @default.
• W2078331588 cites W1643991689 @default.
• W2078331588 cites W1964188164 @default.
• W2078331588 cites W1967709130 @default.
• W2078331588 cites W1968001351 @default.
• W2078331588 cites W1972800342 @default.
• W2078331588 cites W1974137471 @default.
• W2078331588 cites W1983191604 @default.
• W2078331588 cites W1998212419 @default.
• W2078331588 cites W1998534190 @default.
• W2078331588 cites W1998649401 @default.
• W2078331588 cites W2010206955 @default.
• W2078331588 cites W2011503760 @default.
• W2078331588 cites W2020667357 @default.
• W2078331588 cites W2025882375 @default.
• W2078331588 cites W2051228374 @default.
• W2078331588 cites W2061768322 @default.
• W2078331588 cites W2082271987 @default.
• W2078331588 cites W2082659217 @default.
• W2078331588 cites W2085843573 @default.
• W2078331588 cites W2086545953 @default.
• W2078331588 cites W2088350638 @default.
• W2078331588 cites W2093256000 @default.
• W2078331588 cites W2094671820 @default.
• W2078331588 cites W2100126489 @default.
• W2078331588 cites W2112767951 @default.
• W2078331588 cites W2126572359 @default.
• W2078331588 cites W2127460561 @default.
• W2078331588 cites W2132008514 @default.
• W2078331588 cites W2133527614 @default.
• W2078331588 cites W2134886133 @default.
• W2078331588 cites W2136744003 @default.
• W2078331588 cites W2141289992 @default.
• W2078331588 cites W2319073082 @default.
• W2078331588 cites W2340133307 @default.
• W2078331588 cites W4210995338 @default.
• W2078331588 doi "https://doi.org/10.1371/journal.pone.0052680" @default.
• W2078331588 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3580207" @default.
• W2078331588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23300984" @default.
• W2078331588 hasPublicationYear "2013" @default.
• W2078331588 type Work @default.
• W2078331588 sameAs 2078331588 @default.
• W2078331588 citedByCount "15" @default.
• W2078331588 countsByYear W20783315882014 @default.
• W2078331588 countsByYear W20783315882015 @default.
• W2078331588 countsByYear W20783315882016 @default.
• W2078331588 countsByYear W20783315882018 @default.
• W2078331588 countsByYear W20783315882021 @default.
• W2078331588 countsByYear W20783315882022 @default.
• W2078331588 countsByYear W20783315882023 @default.
• W2078331588 crossrefType "journal-article" @default.
• W2078331588 hasAuthorship W2078331588A5001522381 @default.
• W2078331588 hasAuthorship W2078331588A5018955311 @default.
• W2078331588 hasAuthorship W2078331588A5019291640 @default.
• W2078331588 hasAuthorship W2078331588A5019554843 @default.
• W2078331588 hasAuthorship W2078331588A5024687365 @default.
• W2078331588 hasAuthorship W2078331588A5028010133 @default.
• W2078331588 hasAuthorship W2078331588A5051329293 @default.
• W2078331588 hasAuthorship W2078331588A5051377002 @default.
• W2078331588 hasAuthorship W2078331588A5061400306 @default.
• W2078331588 hasAuthorship W2078331588A5065418218 @default.
• W2078331588 hasAuthorship W2078331588A5066770385 @default.
• W2078331588 hasAuthorship W2078331588A5067988831 @default.
• W2078331588 hasAuthorship W2078331588A5076819006 @default.
• W2078331588 hasAuthorship W2078331588A5078737983 @default.
• W2078331588 hasAuthorship W2078331588A5084660598 @default.
• W2078331588 hasBestOaLocation W20783315881 @default.
• W2078331588 hasConcept C126322002 @default.
• W2078331588 hasConcept C137183658 @default.
• W2078331588 hasConcept C2776525014 @default.
• W2078331588 hasConcept C2777374534 @default.
• W2078331588 hasConcept C2778674702 @default.
• W2078331588 hasConcept C2779134260 @default.
• W2078331588 hasConcept C513476851 @default.
• W2078331588 hasConcept C71924100 @default.
• W2078331588 hasConcept C98274493 @default.
• W2078331588 hasConceptScore W2078331588C126322002 @default.
• W2078331588 hasConceptScore W2078331588C137183658 @default.

• next